08:34 AM EDT, 07/14/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Monday that Health Canada expanded the approval of Evkeeza as an adjunct to diet and other low-density lipoprotein cholesterol-lowering therapies to treat children with homozygous familial hypercholesterolemia aged six months or older.

The drug first received Health Canada approval in September 2023 as an adjunct to diet and other therapies for the treatment of adult and pediatric patients aged five years and older with the rare disease.

Evkeeza is already reimbursable and commercially available for patients in Canada via private drug plans and via public drug programs in Quebec, the UK, US, Italy, Japan, the Netherlands, Spain, and Luxembourg and also via programs in 13 additional countries including Austria and France, the company said.

Homozygous familial hypercholesterolemia is a life-threatening condition associated with high levels of low-density lipoprotein cholesterol.